CME Group (CME) Stock Forecast & Price Target

Q: What analysts cover CME Group?

CME Group has been rated by research analysts at Barclays , Deutsche Bank Aktiengesellschaft , Erste Group Bank , Jefferies Financial Group , JPMorgan Chase & Co. , Keefe, Bruyette & Woods , Morgan Stanley , Piper Sandler , Raymond James Financial , Rothschild & Co Redburn , TD Cowen , The Goldman Sachs Group , UBS Group , and Weiss Ratings in the past 90 days.

$240.75 +5.99 (+2.55%)

Closing price 04:00 PM Eastern

Extended Trading

$241.12 +0.37 (+0.15%)

As of 05:51 PM Eastern

Compare

CME Group - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
2

Hold
4

Buy
12

Based on 18 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 2 have given a sell rating, 4 have given a hold rating, and 12 have given a buy rating for CME.

Consensus Price Target

$298.00
23.78% Upside

According to the 18 analysts' twelve-month price targets for CME Group, the average price target is $298.00. The highest price target for CME is $353.00, while the lowest price target for CME is $209.00. The average price target represents a forecasted upside of 23.78% from the current price of $240.75.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CME Analyst Ratings Over Time

Type	Current Forecast 7/7/25 to 7/7/26	1 Month Ago 6/7/25 to 6/7/26	3 Months Ago 4/8/25 to 4/8/26	1 Year Ago 7/7/24 to 7/7/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$298.00	$305.29	$307.59	$259.87
Forecasted Upside	23.78% Upside	18.61% Upside	1.58% Upside	-8.03% Downside
Consensus Rating	Moderate Buy	Hold	Moderate Buy	Hold

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CME Group Stock vs. The Competition

Type	CME Group	Finance Companies	Broader Market
Consensus Rating Score	2.56	2.31	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	26.94% Upside	26.83% Upside	13.49% Upside
News Sentiment Rating	Positive News See Recent CME News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/6/2026	UBS Group 4 of 5 stars	Alex Kramm 3 of 5 stars	Lower Target	Buy	$310.00 ➝ $260.00	+9.89%
7/2/2026	Raymond James Financial 3 of 5 stars	Patrick O'Shaughnessy 2 of 5 stars	Reiterated Rating	Outperform	$320.00	+35.65%
6/30/2026	The Goldman Sachs Group 3 of 5 stars		Lower Target	Sell	$267.00 ➝ $245.00	+9.36%
6/25/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy (B+) ➝ Buy (B)
6/22/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$323.00 ➝ $273.00	+10.81%
6/18/2026	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Allen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$305.00	+20.77%
6/17/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Moley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$320.00	+28.47%
6/11/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Simon Clinch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$316.00 ➝ $323.00	+22.44%
6/5/2026	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
4/23/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Benjamin Budish Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$343.00 ➝ $316.00	+10.60%
Trump's New Dollar (Ad) Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. Watch the free briefing and see the three steps to prepare today
4/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$342.00 ➝ $322.00	+14.77%
4/23/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cyprys Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$362.00 ➝ $353.00	+24.30%
4/16/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Underweight	$266.00 ➝ $271.00	-8.75%
4/9/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$356.00 ➝ $349.00	+16.34%
3/4/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Biggar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
2/5/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashish Sabadra Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$295.00 ➝ $302.00	+2.50%
12/10/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$201.00 ➝ $209.00	-21.53%
9/25/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Allen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$275.00 ➝ $300.00	+13.45%
7/24/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Owen Lau Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$300.00 ➝ $303.00	+9.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:59 PM ET.

Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 6, 2026. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

Here are some ways that investors could benefit from investing in CME Group Inc.:

The current stock price is around $274, which may present a buying opportunity for investors looking for growth in the financial services sector.
CME Group Inc. reported a strong quarterly earnings performance, with earnings per share significantly exceeding consensus estimates, indicating robust financial health and operational efficiency.
The company has a high net margin, suggesting that it retains a significant portion of revenue as profit, which can be attractive for investors seeking companies with strong profitability.
With a market capitalization of approximately $81.53 billion, CME Group Inc. is a major player in the financial markets, providing stability and potential for long-term growth.
The firm has a consistent dividend payout, with an annualized dividend yield of around 2.3%, offering investors a reliable income stream in addition to potential capital appreciation.

CME Group
Bear Case

Investors should be bearish about investing in CME Group Inc. for these reasons:

The price-to-earnings ratio is relatively high, which may indicate that the stock is overvalued compared to its earnings, potentially leading to lower returns if earnings do not grow as expected.
The company's beta is low, suggesting that it may not be as responsive to market movements, which could limit growth opportunities during bullish market conditions.
Despite strong revenue growth, the price-to-earnings-growth ratio indicates that the stock may not be a bargain, as it suggests that the stock price is high relative to its expected earnings growth.
The debt-to-equity ratio is low, which is generally positive, but it may also indicate that the company is not leveraging debt to fuel growth, potentially missing out on expansion opportunities.
Market conditions can be volatile, and as a financial services provider, CME Group Inc. may be affected by fluctuations in trading volumes and market sentiment, which could impact revenue stability.

CME Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $298.00, with a high forecast of $353.00 and a low forecast of $209.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last year. There are currently 2 sell ratings, 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CME shares.

According to analysts, CME Group's stock has a predicted upside of 23.78% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 3 downgrades and 2 upgrades by analysts.

CME Group has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Erste Group Bank, Jefferies Financial Group, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Piper Sandler, Raymond James Financial, Rothschild & Co Redburn, TD Cowen, The Goldman Sachs Group, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like CME Group more than other "finance" companies. The consensus rating for CME Group is Moderate Buy while the average consensus rating for "finance" companies is Hold. Learn more on how CME compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With CME Group Recommendations

This page (NASDAQ:CME) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CME Group (CME) Stock Forecast & Price Target